Filtered By:
Drug: Plavix
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1913 results found since Jan 2013.
CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research
P160/223 Acute stroke with treatment of tandem lesions under triple antiplatelet therapy: procedural saftey, stent patency and outcome at 90 days
ConclusionTL treatment under triple AP was safe in our experience, resulting in a low rate of restenosis and with favorable outcome in 92%. The influence of comorbidities on restenosis could be negligible within the described follow-up period.Disclosure of InterestPhilipp von Gottberg: Nothing to disclose.Ali Khanafer: Nothing to discloseVictoria Hellstern: Proctering for phenox GmbH.Alexandru Cimpocca: Nothing to disclose.Hans Henkes: Proctoring for phenox GmbH, Co-Founder and Co-Owner of CONTARA GmbH
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Philipp, V. G., Khanafer, A., Hellstern, V., Cimpoca, A., Bäzner, H., Henkes, H. Tags: 2.3 ISCHEMIC - Treatment Source Type: research
P005/44 Using the pEGASUS-stent with antithrombogenic properties and single antiplatelet therapy in a case of thrombectomy
IntroductionRescue stenting is used more and more in stroke cases with large-vessel-occlusion or medium-vessel-occlusion refractory to mechanical thrombectomy. The pEGASUS-stent(Phenox) represents a device which is equipped with a hydrophilic polymer coating(HPC) with antithrombogenic properties. The coating allows for implantation under single antiplatelet therapy, thus possibly reducing the risk of bleeding in acute stroke cases.Case HistoryA 79-year-old woman was rushed to emergency room due to left-sided hemiparesis and National-Institutes-of-Health-Stroke-Scale(NIHSS) of 14. Computed-tomography-image showed an occlusi...
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Krug, N., Schulze-Zachau, V., Ntoulias, N., Psychogios, M. Tags: 4.3 CASE PROPOSAL - Acute ischemic stroke Source Type: research
P012/110 Flow diversion in a giant fusiform M2 aneurysm: very delayed parent vessel occlusion and post-thrombectomy re-in-stent thrombosis
ConclusionVery delayed in-stent thrombosis and subsequent parent vessel occlusion can occur after flow diversion procedures.Disclosure of InterestAK: Nothing to discloseMB: Consultant for Microvention, Cerenovus, Acandis, and RapidJF: The Co-author reports personal fees from Consultant for Acandis, Cerenovus, Medtronic, Microvention, Phenox, Penumbra, Roche, Tonbridge outside of the submitted work. He is a member of the Executive Board of the scientific societies DGNR and the President of ESMINT and holds Stock in Vastrax LLC and Tegus.
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Kyselyova, A. A., Fiehler, J., Bester, M. Tags: 4.3 CASE PROPOSAL - Acute ischemic stroke Source Type: research
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA). However, genetic polymorphisms of CYP2C19...
Source: BMC Neurology - August 14, 2023 Category: Neurology Authors: Mingxia Li, Qianru Yang, Jiankuan Shi, Xiaolong Zhang, Hong Lin and Fangfang Ge Tags: Research Source Type: research
Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study
ConclusionIn our study involving patients with acute ischemic stroke who had undergone intracranial stenting, aspirin-ticagrelor was not found to be superior to aspirin-clopidogrel in reducing the rate of ischemic vascular events. The risk of bleeding did not differ between the two groups. Aspirin-ticagrelor does not lower total restenosis and symptomatic restenosis risk at follow-up.
Source: Frontiers in Neurology - August 11, 2023 Category: Neurology Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network Meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Antiplatelet therapy in Neurointervention
Semin Neurol DOI: 10.1055/s-0043-1771383The aim of this review is to provide an overview of the use of antiplatelet medication in neurointervention, with a focus on the clinical indications for antiplatelet use in both preventing and reducing platelet aggregation. This review will cover current antiplatelet medications, pharmacokinetics, and pharmacodynamics. We will provide an overview of different endovascular devices and discuss the antiplatelet regimes in neurointervention, highlighting gaps in evidence and scope for future studies.Two randomized controlled trials have evaluated antiplatelet use in the setting of acute...
Source: Seminars in Neurology - August 10, 2023 Category: Neurology Authors: Ma, Alice Detaram, Harshil Dharamdasani Steinfort, Brendan Harrington, Tim Nguyen, Thanh N. Abdalkader, Mohamad Siopis, George Bath, Philip M. Dhillon, Permesh Singh Podlasek, Anna Qureshi, Adnan I. Qiu, Zhongming Krishnan, Kailash Tags: Review Article Source Type: research
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research
Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study
Conclusion: In real practice, ticagrelor swi tching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.
Source: PLoS One - August 4, 2023 Category: Biomedical Science Authors: Phornpaka Ueapornpanith Source Type: research
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis
ConclusionsWhen compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
Source: American Journal of Cardiovascular Drugs - August 2, 2023 Category: Cardiology Source Type: research
Use of Tirofiban to Prevent Ischemic Events in Patients with CYP2C19 Loss-of-Function Alleles during Flow Diversion of Intracranial Aneurysm: A Multicenter Cohort Study
This study supports CYP2C19 genotyping before flow diversion because LOF alleles increase the risk of ischemic events. Prophylactic use of tirofiban may help reduce ischemic events in LOF allele carriers.
Source: Translational Stroke Research - July 31, 2023 Category: Neurology Source Type: research
